Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Gynaecologisch Oncologisch Centrum Zuid
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
58High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03458221CT.gov Signal TrAnsduction Pathway Activity Analysis in OVarian cancER | — | Recruiting | — | — | — |
NCT03154281CT.gov Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast | — | Completed | — | — | — |
NCT02188550CT.gov Single Arm Trial With Combination of Everolimus and Letrozole in Treatment of Platinum Resistant Relapse or Refractory or Persistent Ovarian Cancer/Endometrial Cancer | — | Unknown | — | — | — |
NCT02407509CT.gov Phase I Trial of VS-6766 Alone and in Combination With Everolimus | — | Completed | — | — | — |
NCT01031381CT.gov Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer | — | Completed | — | — | — |
NCT01149434CT.gov Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Ovarian Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Everolimus (this asset) | Gynaecologisch Oncologisch Centrum Zuid | P2/3 | B · 58 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| TIL | Inge Marie Svane | P2 | BB |
| Olaparib | Shandong University | P4 | BB |
| Cis-Diamminedichloroplatinum Ii | Kalinski, Pawel, MD, PhD | P3 | BB |
| Adriamycin | Genmab | P3 | BB |
| Carboplatin | Fudan University | P4 | BB |
| OTL-38 | On Target Laboratories, LLC | P4 | BB |
| Irinotecan | ARCAGY/ GINECO GROUP | P4 | BB |
+42 more in the Ovarian Cancer cohort
Other indications for Everolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 76 |
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 75 |
| Hodgkins Lymphoma | — | P2 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Everolimus in Ovarian Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/everolimus-ovarian-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →